Moderna Omicron booster cleared in Canada for children and adolescents
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) announced Friday that Health Canada authorized its COVID-19 booster shot targeting the Omicron subvariant BA.1 for use in those aged 6 â 17.
Accordingly, the messenger-RNA-based bivalent vaccine, mRNA-1273.214, will be allowed as a booster shot in Canada for children and adolescents who have completed a primary series with any authorized COVID shot or a previous booster.

The authorization limits mRNA-1273.214 dosage to 25 Î¼g for children aged 6 â 11 years and 50 Î¼g booster dose for adolescents aged 12 -17 years.
Canada has previously authorized mRNA-1273.214 and the companyâs BA.4/ BA.5 targeting Omicron booster mRNA.1273.222 for use in those aged 18 years and above.

Moderna (MRNA) shares extended losses today after the company reported mixed findings from a late-stage trial for its mRNA-based flu vaccine mRNA-1010.

Citing a technical analysis, Seeking Alpha contributor Muhammad Umair foresees continued downward pressure for company shares.